Prestige Consumer Healthcare (PBH) Stock: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$49.46
1.54 (3.21%)
▲
5d:
+0.53%
30d:
+7.71%
90d:
-0.4%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PBH shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PBH shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$70.05
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$43.50
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $49.46, which is considered extended relative to its 30-day fair value range of $45.86 to $48.77. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.3) compared to its historical average (11.6). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PBH is showing sideways momentum. The price is approaching resistance at $50.84. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $67.80 (+37.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PBH is showing sideways momentum. The price is approaching resistance at $50.84. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $67.80 (+37.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$45.86 -
$48.77
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.7%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 37.1% below Wall St target ($67.80)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$45.86 -
$48.77
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$47.48
Resistance Level
$50.84
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.33
Wall Street Target
$67.80
(+37.1%)
Revenue Growth (YoY)
6.5%
Earnings Growth (YoY)
-35.8%
Profit Margin
15.6%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
10.3 vs 11.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$47.63
(-4%)
2-Year Target
$45.87
(-7%)
3-Year Target
$44.17
(-11%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$49.61
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 5.5%)
$111.61
(+126%)
Base:
(SPY PE: 10.3, Growth: 5.5%)
$58.05
(+17%)
Bear:
(PE: 8.8, Growth: 5.5%)
$49.34
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 13.42 | Current EPS (TTM): $3.57
Bull Case
$70.71
(+43%)
Analyst growth 34.1%, PE expands to 14.8
Base Case
$64.28
(+30%)
Market implied 34.1%, PE stable at 13.4
Bear Case
$32.59
(-34%)
Severe decline -20.0%, PE contracts to 11.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.3 to 11.6
Stabilization Target:
$55.55
(+12.3%)
PE Expansion Potential:
+12.3%
Share & Embed Analysis
Last updated: October 22, 2026 6:48 PM ET
Data refreshes hourly during market hours. Next update: 7:48 PM
Data refreshes hourly during market hours. Next update: 7:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
